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Abstract 
 
Macroautophagy/autophagy, a defense mechanism against aberrant stresses, in neurons 
counteracts aggregate-prone misfolded protein toxicity. Autophagy induction might be beneficial in 
neurodegenerative diseases (NDs). The natural compound trehalose promotes autophagy via TFEB 
(transcription factor EB), ameliorating disease phenotype in multiple ND models, but its 
mechanism is still obscure. We demonstrated that trehalose regulates autophagy by inducing rapid 
and transient lysosomal enlargement and membrane permeabilization (LMP). This effect correlated 
with the calcium-dependent phosphatase PPP3/calcineurin activation, TFEB dephosphorylation and 
nuclear translocation. Trehalose upregulated genes for the TFEB target and regulator Ppargc1a, 
lysosomal hydrolases and membrane proteins (Ctsb, Gla, Lamp2a, Mcoln1, Tpp1) and several 
autophagy-related components (Becn1, Atg10, Atg12, Sqstm1/p62, Map1lc3b, Hspb8 and Bag3) 
mostly in a PPP3- and TFEB-dependent manner. TFEB silencing counteracted the trehalose pro-
degradative activity on misfolded protein causative of motoneuron diseases. Similar effects were 
exerted by trehalase-resistant trehalose analogs, melibiose and lactulose. Thus, limited lysosomal 
damage might induce autophagy, perhaps as a compensatory mechanism, a process that is beneficial 
to counteract neurodegeneration.  
 
Keywords: amyotrophic lateral sclerosis; autophagy; calcineurin; galectin-3; lactulose; 
lysosomes; melibiose; motoneuron diseases; neurodegeneration; protein quality control; spinal and 
bulbar muscular atrophy; TFEB; trehalose. 
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Abbreviations 
ALS: amyotrophic lateral sclerosis; AR: androgen receptor; ATG: autophagy related; AV: 
autophagic vacuole; BAG3: BCL2-associated athanogene 3; BECN1: beclin 1, autophagy related; 
CASA: chaperone-assisted selective autophagy; CTSB: cathepsin b; DAPI: 4',6-diamidino-2-
phenylindole; DMEM: Dulbecco's modified Eagle's medium; EGFP: enhanced green fluorescent 
protein; fALS, familial amyotrophic lateral sclerosis; FRA: filter retardation assay; GAPDH: 
glyceraldehyde-3-phosphate dehydrogenase; GLA: galactosidase,  alpha; HD: Huntington disease; 
hIPSCs: human induced pluripotent stem cells;  HSPA8: heat shock protein 8; HSPB8: heat shock 
protein 8; IF: immunofluorescence analysis; LAMP1: lysosomal-associated membrane protein 1; 
LAMP2A: lysosomal-associated membrane protein 2A; LGALS3: lectin, galactose binding, soluble 
3; LLOMe: L-leucyl-L-leucine methyl ester; LMP: lysosomal membrane permeabilization; Lys: 
lysosomes; MAP1LC3B: microtubule-associated protein 1 light chain 3 beta; MCOLN1: mucolipin 
1; mRNA: messenger RNA; MTOR: mechanistic target of rapamycin kinase; NDs: 
neurodegenerative diseases; NSC34: neuroblastoma x spinal cord 34; PBS: phosphate-buffered 
saline; PD: Parkinson disease; polyQ: polyglutamine; PPARGC1A: peroxisome proliferative 
activated receptor, gamma, coactivator 1 alpha; PPP3CB: protein phosphatase 3, catalytic subunit, 
beta isoform; RT-qPCR: real-time quantitative polymerase chain reaction; SBMA: spinal and 
bulbar muscular atrophy; SCAs: spinocerebellar ataxias; siRNA: small interfering RNA; SLC2A8: 
solute carrier family 2, (facilitated glucose transporter), member 8; smNPCs: small molecules of 
neural progenitors cells; SOD1: superoxide dismutase 1, soluble; SQSTM1/p62: sequestosome 1; 
STED: stimulated emission depletion;  STUB1: STIP1 homology and U-box containing protein 1; 
TARDBP/TDP-43: TAR DNA binding protein; TFEB: transcription factor EB; TPP1: tripeptidyl 
peptidase I; TREH: trehalase (brush-border membrane glycoprotein); WB: western blotting; 
ZKSCAN3: zinc finger with KRAB and SCAN domains 3 
 
 4 
 5 
Introduction 
 
Macroautophagy (autophagy hereafter) is a well-conserved degradative pathway, which is part of 
intracellular quality control systems in almost all eukaryotic cell types. The major physiological 
role of autophagy is to maintain a regular energy supply by recycling macromolecules, especially 
during starvation or under several types of cell stresses [1]. Autophagy also assures the renewal of 
intracellular molecular and macromolecular components eliminating damaged proteins and 
organelles. In addition, autophagy acts against infection by destroying invading intracellular 
bacteria and viruses [1]. Mutations in genes correlated to autophagy are associated with different 
pathological conditions, such as cancer and neurodegenerative diseases (NDs) [2]. In these 2 classes 
of human diseases, autophagy is activated and/or blocked in a way that may differentially correlate 
with disease progression [2]. In particular, in NDs associated with the accumulation of misfolded 
proteins (e.g., Parkinson disease [PD], Huntington disease [HD], amyotrophic lateral sclerosis 
[ALS], spinal and bulbar muscular atrophy [SBMA], several types of spinocerebellar ataxias), 
activation of autophagy represents one of the most efficient arms of the protein quality control 
system, which removes neurotoxic protein species [3]. An insufficient or blocked autophagic flux 
generally correlates with misfolded protein accumulation into intracellular inclusions in different 
neuronal compartments (nucleus, cytoplasm, axons, mitochondria, endoplasmic reticulum, etc.) [4-
6]. Because of that, several investigators have attempted to pharmacologically potentiate the 
autophagic flux in neuronal cells (or other cell types involved in disease, such as glial or muscle 
cells) to enhance the clearance of neurotoxic misfolded proteins.  
Interestingly, among autophagy inducers, the natural disaccharide trehalose, widely used as 
nutraceutical, preservative, and humectant, exerts a potent pro-autophagic activity both in vitro and 
in vivo [7-9]. Notably, trehalose enhances the clearance of several different mutant misfolded 
proteins responsible for neuronal death, in different neuronal models of adult onset NDs [9-14]. In 
vivo, trehalose promotes survival of several mice models of ND (human tauopathy, HD, PD, ALS, 
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oculopharyngeal muscular dystrophy) [13,15-26], either/both by delaying onset or/and by slowing 
down progression of the diseases, generally with an amelioration of the symptoms associated with 
the disease. Despite these very promising observations, the mechanism by which trehalose activates 
and increases the autophagic flux is still obscure. Trehalose induces de novo expression of 2 
autophagic proteins, SQSTM1/p62 and MAP1LC3B, and activates the conversion of MAP1LC3B-I 
to its autophagosome-associated lipidated form LC3-II [9-11,13,27-29]. Trehalose also induces 
expression of a potent facilitator of the autophagic flux, the small heat shock protein HSPB8 [10]. 
However, pro-autophagic activity of trehalose does not appear to depend on the MTOR 
(mechanistic target of rapamycin kinase) pathway, an important sensor of the cell nutrient status 
[9,16,24,28,30].  
It has been suggested that trehalose activity could be mediated by the inhibition of a glucose 
transporter [31,32], SLC2A8/GLUT8  (solute carrier family 2, [facilitated glucose transporter], 
member 8), thus preventing glucose uptake into cells [32]. The reduction of glucose uptake could 
produce an apparent “starvation”, which activates autophagy [32,33]. However, it has been shown 
that trehalose itself needs to be internalized in cells to activate autophagy, because deletion of the 
gene encoding SLC2A8, which also acts as a trehalose importer, blocks the ability of trehalose to 
induce autophagy [33].  
Interestingly, trehalose induces nuclear translocation of TFEB (transcription factor EB) [30, 
34] a master regulator of the expression of many autophago-lysosomal components [35-40]. Several 
kinases have been suggested to mediate this activity. For example, by regulating FOXO3/FOXO3A 
phosphorylation, trehalose could activate the adenosine 5'-monophosphate-activated protein kinase, 
thereby enhancing the activity of CARM1 (coactivator-associated arginine methyltransferase 1), a 
TFEB co-activator [32]; alternatively, trehalose could inhibit AKT, a kinase which retains TFEB in 
its inactive phosphorylated status in the cytoplasm [30].  
Here, we show that trehalose can regulate autophagy by a mechanism involving changes in 
lysosomes with their rapid enlargement and transient permeabilization upon treatment, as we 
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observed by super-resolution microscopy and electron microscopy. We find that such lysosomal 
modifications correlate with the activation of PPP3CB/calcineurin (protein phosphatase 3, catalytic 
subunit, beta isoform), likely via lysosomal calcium release. Activated PPP3CB targets and 
specifically dephosphorylates TFEB, inducing translocation from the cytoplasm to the nucleus and 
conferring transcriptional competence. Thus, transient lysosomal damage could directly promote 
TFEB activation, ultimately activating autophagy upon trehalose stimulation. 
 
 8 
Results 
 
Trehalose induces TFEB nuclear translocation and activation of autophagy-linked genes in 
immortalized motoneurons 
Trehalose treatment counteracts misfolded protein toxicity in models of ND, including ALS and 
SBMA, in which motoneurons die. Thus, we initially evaluated whether trehalose induces TFEB 
nuclear translocation in NSC34, an immortalized motoneuronal cell line. Confocal 
immunofluorescence (IF) microscopy showed that in untreated conditions endogenous TFEB was 
confined to the cell cytoplasm (Figure 1A, quantification in 1B). After 2 h of trehalose treatment, a 
different pattern of distribution was appreciable, with TFEB appearing in the nucleus. However, 
only at 18-24 h of trehalose treatment did a clear nuclear staining become detectable, with a 
massive nuclear compartmentalization at 48 h.  
To confirm trehalose-induced nuclear relocalization of TFEB, we performed a fractionation 
experiment (Figure 1C). We found that the nuclear TFEB levels started to rise 18 h after trehalose 
treatment and gradually increased at later stages. Conversely, cytoplasmic TFEB protein levels 
were sharply decreased after 48 h of trehalose treatment. These data confirm previous findings that 
trehalose may induce TFEB activation and suggest that the TFEB-mediated induction of autophagy 
might be a late event of trehalose treatment.  
We next tested whether trehalose treatment could lead to transcriptional activation of TFEB 
targets. To this end, we analyzed whether TFEB translocation correlated with an enhanced 
transcription of selected pro-autophagic genes. Figure 1 panels D-M show the RT-qPCR performed 
on RNAs obtained from trehalose-treated or control (glucose treated) NSC34 cells at different times 
after treatments. Trehalose was unable to modify the expression levels of Tfeb (Figure 1D) whereas 
it specifically enhanced the expression of genes coding for the autophagy inducer BECN1 (Figure 
1L), SQSTM1/p62 (sequestosome 1) (Figure 1F), which is an autophagy receptor, and its interactor 
MAP1LC3B (microtubule-associated protein 1 light chain 3 beta) (Figure 1G), which is required 
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for autophagosome formation. The enhanced expression of these genes was present after 48 h of 
treatment, in line with the observed TFEB nuclear translocation (Figure 1A and C). Trehalose also 
induced the de novo expression of 2 autophagy related (Atg) genes, coding respectively for the E2-
like enzyme ATG10 (Figure 1H) and for ATG12 which, in conjunction with ATG5, acts as an E3-
like enzyme required for the MAP1LC3B lipidation and activation (Figure 1I). However, these 2 
Atg genes differentially respond to TFEB activation, because Atg10 was significantly induced by 
trehalose at 18-24 h, whereas Atg12 was induced at a later time point (48 h after trehalose 
exposure). After 48 h of trehalose treatment, we found a robust increase of the expression levels of 
an additional TFEB responder, Ppargc1A (peroxisome proliferative activated receptor, gamma, 
coactivator 1 alpha), that transcriptionally regulates genes involved in nutrient metabolism and acts 
as a master regulator of mitochondrial biogenesis [41-43] (Figure 1M). Surprisingly, trehalose 
treatment also significantly induced the expression of Zkscan3 (zinc finger with KRAB and SCAN 
domains 3) (Figure 1E), coding for a master repressor of autophagy, which acts as a physiological 
antagonist of TFEB [44]. Changes in Zkscan3 expression were detectable after 48 h of trehalose 
treatment, suggesting that its expression might be an attempt to limit the autophagy induction 
associated with TFEB activation.  
In several NDs, clearance of misfolded proteins by autophagy is assisted by the chaperone-
assisted selective autophagy (CASA) complex [45-48], which depends on HSPB8. HSPB8 is a 
chaperone induced by trehalose, which facilitates autophagic degradation of misfolded proteins 
acting both as a limiting factor for the CASA complex and a regulator of the proteasome and 
autophagic routing systems [10,45,49-54]. In the CASA complex, HSPB8 (heat shock protein 8) 
binds BAG3 (BCL2-associated athanogene 3) and the HSPA8 (heat shock protein 8)-STUB1 
(STIP1 homology and U-box containing protein 1) complex allowing STUB1-mediated 
ubiquitination of target misfolded substrates followed by SQSTM1/p62 recognition and insertion 
into the autophagy pathway. We thus analyzed whether expression of HSPB8 and BAG3 was 
modified by trehalose treatment (Figures 1J and K). Hspb8 expression was found induced by 
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trehalose treatment, whereas Bag3 was induced by both trehalose and glucose treatment, possibly as 
a general response to osmotic variations. Hspb8, Sqstm1/p62, Map1Lc3b and Atg12 inductions were 
maximal at 48 h after trehalose exposure, suggesting a cooperative activity between these proteins. 
Overall, these data suggest that trehalose acts by inducing genes that are typically controlled by 
TFEB. 
 
TFEB downregulation prevents trehalose-mediated autophagy induction. 
While trehalose activates expression of autophagy genes in a time window compatible with nuclear 
translocation of endogenous TFEB, it is unclear if these 2 effects are directly related. To assess this, 
we next determined whether trehalose requires TFEB to exert its action. Tfeb siRNA efficiently 
downregulated TFEB protein (Figure 2A) and mRNA (Figure 2D) levels, while a non-targeting 
siRNA was inactive. Interestingly, in line with their transcriptional activation (Figures 1F and 1G), 
trehalose treatment strongly induced SQSTM1/p62 and MAP1LC3B-I (as well as its conversion to 
the MAP1LC3B-II lipidated form, required to sustain autophagy flux); this effect of trehalose was 
severely blunted when TFEB was downregulated with its specific siRNA (Figure 2A, 
quantifications 2B and 2C). The involvement of TFEB in mediating the action of trehalose on these 
2 genes was also confirmed by RT-qPCR analysis (Figure 2G and 2H), which revealed that TFEB 
downregulation resulted in a significant decrease of both Sqstm1/p62 and Map1Lc3b as well as of 
Ppargc1A expression (Figure 2F). Notably, TFEB downregulation did not affect trehalose-induced 
expression of the Zkscan3 gene, suggesting that expression of this autophagy repressor is 
independent of a transcriptional regulation mediated by TFEB (Figure 2E). Similarly, TFEB 
downregulation did not modify Hspb8 expression (Figure 2I).  We also analyzed other TFEB regu–
lated genes involved in lysosomal dynamics: those encoding lysosomal enzymes, Ctsb (cathepsin b) 
(Figure 2J) Gla (galactosidase, alpha) (Figure 2K), and Tpp1 (tripeptidyl peptidase 1) (Figure 2N), 
and lysosomal membrane proteins, Lamp2a (lysosomal-associated membrane protein 2A) (Figure 
2L) and the calcium channel Mcoln1 (mucolipin 1) (Figure 2M). Trehalose treatment induced a 
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robust increase in the expression of most of these lysosomal genes, except for Gla, which was 
marginally induced after trehalose treatment. In line with our previous observation, also in this case, 
TFEB downregulation markedly reduced the trehalose-induced expression of these genes. These 
results indicate that, upon trehalose treatment, TFEB is crucial for induction of autophagy and 
lysosomal functionality, but dispensable for expression of Zkscan3 and Hspb8. 
 
Trehalose promotes clearance of neurotoxic misfolded proteins in a TFEB-dependent manner. 
To verify whether the action of trehalose specifically on polyQ-containing proteins in NDs is 
mediated by TFEB, we made use of cells expressing a mutant AR (androgen receptor), which 
contains an elongated polyglutamine tract (ARpolyQ). ARpolyQ is responsible for spinal and 
bulbar muscular atrophy, and others and we have previously demonstrated that its cellular 
aggregation is cleared following trehalose treatment [10,27,29]. One advantage of the ARpolyQ cell 
model is that aggregation and associated neurotoxicity is triggered by the ligand testosterone 
[10,27,55-60]. Consistent with this, using a filter retardation assay (FRA) and western blotting 
(WB) [10,49,58,61,62] we found that aggregation of AR.Q46 (a form of ARpolyQ containing 46 
polyglutamines) is triggered by 10 nM testosterone, and that trehalose reduces the monomeric 
AR.Q46 (Figure 3A), a process that we already demonstrated to be mediated by autophagy 
activation [10,27], and fully reverts AR.Q46 aggregation (Figure 3B, quantification in Figure 3C). 
Importantly, TFEB downregulation completely abolished the prodegradative activity of trehalose on 
testosterone-induced monomeric and aggregated AR.Q46 forms (Figures 3A and B), proving that 
trehalose enhances ARpolyQ clearance via the TFEB pathway. These data have been confirmed 
also in iPSCs derived from SBMA patients and differentiated to motoneuronal-like cells. In fact, we 
found that trehalose reduced the overall levels of AR.Q51 in a WB assay (Figure 3D) increasing the 
MAP1LC3B-I to MAP1LC3B-II conversion. 
We next wanted to extend our evaluation of TFEB involvement in aggregate clearance of 
the protein TARDBP/TDP-43 (TAR DNA binding protein) typically characterizing sporadic forms 
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of ALS and of fronto-lateral temporal dementia, as well as familial forms of ALS (fALS) linked to 
several human SOD1 (superoxide dismutase 1, soluble) mutations. In patients and cellular models 
of these diseases, TARDBP is cleaved releasing a neurotoxic fragment of 25 kDa (TARDBP-
25/TDP-25), and we recently reported that this cleaved fragment is highly prone to aggregate into 
sodium dodecyl sulfate-insoluble species resistant to autophagy clearance and capable of impairing 
autophagy [63,64]. While no significant variations were found for the soluble fraction of the GFP-
tagged TARDBP-25 fragment evaluated in WB (Figure 3E), similar to the AR model, we found that 
trehalose induced the clearance of the aggregated form of this fragment retained on FRA (Figure 
3F, quantification in Figure 3G). Also in this case, the pro-degradative activity of trehalose was 
abolished when TFEB was downregulated (Figure 3F), suggesting that TARDBP-25 clearance by 
trehalose requires the TFEB pathway. Then we studied the fALS models based on mutant SOD1, 
using immortalized motoneurons expressing GFP-SOD1A4V or GFP-SOD1G93A, 2 point mutations 
causative of fALS. We observed that trehalose induced the clearance of insoluble GFP-SOD1 
mutant proteins (Figures 3I and 3L; quantification in Figures 3J and 3M), whereas the soluble form 
remained similar in WB. TFEB downregulation counteracted trehalose-induced clearance of GFP-
SOD1 mutant proteins. Collectively, these results indicate that the TFEB pathway is a critical 
mediator of autophagy clearance of misfolded proteins in NDs. 
 
Trehalose-induced TFEB activation is mediated by PPP3.  
Because we demonstrated that the pro-autophagic activity of trehalose on misfolded protein 
requires the presence of TFEB, we searched for the molecular mechanism used by trehalose to 
activate TFEB. TFEB nuclear translocation and transcriptional activation is controlled through 
dephosphorylation by PPP3CB [38-40]. Thus, in trehalose-treated cells, we evaluated TFEB 
translocation upon downregulation of Ppp3cb. By both WB (Figure 4A) and IF (Figure 4B, 
quantification in Figure 4C), we observed that Ppp3cb downregulation strongly reduced trehalose-
induced nuclear translocation of TFEB. Despite this, trehalose did not directly affect Ppp3cb levels, 
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because no variation in mRNA levels was observed by RT-qPCR after trehalose exposure (Figure 
4D). Interestingly, we also found that PPP3CB activity was likely to be required to mediate TFEB 
translocation to the nucleus in trehalose-treated cells. In fact, we observed that the 
immunosuppressant cyclosporin A, a potent PPP3CB inhibitor [65], reduced nuclear translocation 
of TFEB (Figure 4E), and counteracted dephosphorylation at p-Ser142 when TFEB was 
overexpressed (Figures 4G and H). In addition, in WB the TFEB immunoreactive band was 
normally upshifted in the absence of trehalose appearing as a doublet, while the ratio of the 2 TFEB 
bands was specifically reduced by trehalose (Figures 2A and 4A), suggesting that TFEB was 
dephosphorylated in these conditions. These experiments indicate that PPP3CB activity is required 
for TFEB delocalization upon trehalose treatment. 
 
Trehalose induces transient lysosome damage. 
PPP3CB is a Ca2+ and calmodulin-dependent Ser/Thr protein phosphatase. It has been recently 
shown that PPP3CB activity required for TFEB dephosphorylation can be triggered by the 
lysosomal fusion and other lysosomal events that lead to Ca2+ release [39,40]. To evaluate the effect 
of trehalose on lysosomes, we analyzed their morphology and abundance by electron microscopy 
(EM) of treated and untreated NSC34 cells. While in control cells occasional lysosomes were 
visible, treated cells displayed several enlarged lysosomes whose size increased after incubation 
with trehalose, doubling their size at 24-48 h (Figure 5A). Interestingly, at 2 and 6 h of trehalose 
treatment more than half of the enlarged lysosomes in treated cells also presented gaps in their 
membrane (Figure 5C, and quantification in Figure 5D), suggesting that trehalose treatment 
compromises the integrity of the lysosome limiting membrane. Starting from 24 h, the trehalose-
induced lysosomal damage became attenuated, and at 48 h the overall number of damaged 
lysosomes was found to be greatly reduced. Collectively, these data support the hypothesis that the 
trehalose induction of lysophagy triggers the clearance of damaged lysosomes and restores 
lysosomal homeostasis (Figures 5C, and  5D).  
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We also performed a time course analysis following the effect of trehalose on SQSTM1/p62 
levels and MAP1LC3B (I vs II) activation up to 48 h. We found that, already at 18 h, trehalose 
strongly induced a physiological response of both autophagic markers; this activation lasted up to 
48 h (Figure 5E). Thus, autophagy activation paralleled the TFEB nuclear translocation and activity 
which increased at 18 h and reached its maximal level at 48 h (Figure 1). 
To assess whether trehalose treatment leads to lysosome membrane permeabilization (LMP) 
that could cause Ca2+ release from lysosomes, we transfected NSC34 cells with a plasmid encoding 
EGFP-LGALS3, a fluorescent form of LGALS3/galectin 3 (lectin, galactose binding, soluble 3), 
which binds β-galactoside residues present in the lysosomal lumen [66]. We then analyzed cells 
counterstained to detect the lysosomal membrane marker LAMP1 (lysosomal-associated membrane 
protein 1) by confocal and super-resolution microscopy. LGALS3 is normally diffuse in the 
cytoplasm and nucleus, but is sequestered inside lysosomes to mark individual lysosomes when 
LMP is induced [66,67]. Consistent with this, in basal conditions, we found EGFP-LGALS3 diffuse 
throughout the cell, while 2 h and 6 h of trehalose treatment resulted in a 3-fold increase of EGFP-
LGALS3-positive puncta accompanied by a global reduction of nuclear and cytoplasmic EGFP-
LGALS3 in its diffuse form. As a positive control to induce LMP, we treated with the compound L-
leucyl-L-leucine methyl ester (LLOMe) [68], which resulted in significant puncta formation 
(Figures 6A and 6B). From 18 h to 48 h of trehalose treatment, EGFP-LGALS3 puncta per cells 
decreased until levels similar to basal conditions (Figure 6B). WB analysis confirmed that after an 
initial accumulation of EGFP-LGALS3 (2 and 6 h), the protein levels decreased during the time 
period of treatment, indicating the clearance of the protein (Figure 6C). By STED microscopy, we 
observed the appearance of ring-like EGFP-LGALS3 structures, positive for LAMP1 in cells 
treated for 6 h with trehalose (Figure 6D), indicating that lysosomes are permeabilized.   
Strikingly, we observed a gradual decrease between 2 and 18 h of trehalose treatment in 
fluorescence associated with the dye LysoTracker Green that binds H+ in the lysosomal lumen, 
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which is reverted by 48 h of treatment (Figure 6E).  Overall, these data indicate that trehalose 
induces lysosomal enlargement and damage, leading to an increase in LMP in treated cells.  
 
The analogs melibiose and lactulose mimic the pro-autophagic effects of trehalose 
Trehalose effects have already been assayed in several different mice models of NDs linked to 
misfolded protein neurotoxicity with promising results [11,15-19,21-25]. However, a large fraction 
of trehalose is degraded by intestinal TREH (trehalase [brush-border membrane glycoprotein]), 
when this compound is taken orally [69]. Thus, if approved for human use, trehalose is likely to be 
inefficient, restricting its use to intravenous injections. To circumvent such potential limitation, we 
evaluated whether trehalose analogs, already described as TREH-resistant and capable of activating 
autophagy and to remove misfolded protein species [70,71], trigger responses similar to those 
observed here upon trehalose treatment. Interestingly, we found that both melibiose and lactulose 
stimulated nuclear translocation of endogenous TFEB, both in IF (Figure 7A) and in cell 
fractionation assay in WB (Figure 7B, quantification in Figure 7C). In addition, induction of TFEB 
translocation obtained both with melibiose and lactulose was partially reverted by cyclosporin A 
(Figures 8A and B, respectively).  
This finding suggests that, as is the case with trehalose, upon melibiose or lactulose 
treatment, the phosphatase activity of PPP3CB might be required for induction of TFEB activation, 
but Tfeb de novo transcription was not required (Figure 8C). Both TREH-resistant molecules 
induced the expression of Zkscan3 (Figure 8D), Sqstm1/p62 (Figure 8E), Map1Lc3b (Figure 8F), 
Hspb8 (Figure 8G) and Bag3 (Figure 8H) with an intensity analogous to that observed in trehalose 
treatments at the same doses. Finally, both compounds induced EGFP-LGALS3-positive puncta to 
a similar extent to trehalose (Figure  8I), indicating that they are also able to induce LMP.   
To assess the pro-degradative activity of melibiose and lactulose in comparison to trehalose, 
we performed FRA analysis. We observed that both trehalose analogs were able to revert AR.Q46 
aggregation, with effects comparable to trehalose  (Figure 9A). Melibiose and lactulose were able to 
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induce the clearance of soluble ARpolyQ, effects fully counteracted by TFEB downregulation 
(Figures 9C and D, respectively), suggesting that their pro-degradative activities require this 
transcription factor as we showed in the case of trehalose. 
In summary, all the experiments performed using the TREH-resistant analogs of trehalose 
proved that they act via LMP and TFEB, suggesting that they might be effective alternatives to 
trehalose. 
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Discussion  
 
Trehalose is a natural disaccharide used in food production that recently was found able to enhance 
the autophagic removal of neurotoxic misfolded proteins prone to aggregate [7-14], ameliorating 
disease phenotype in several cell and mouse models of NDs (including human tauopathy, HD, PD, 
ALS, oculopharyngeal muscular dystrophy) [13,15-26]. Trehalose stimulates the nuclear 
translocation of TFEB and the expression of genes regulating autophagy [9-11,13,27-30].  To 
trigger autophagy, trehalose must be imported inside the cells by SLC2A8/GLUT8 [31,32], and its 
action does not involve the MTOR pathway [9,16,24,28,30]. We excluded any direct activity of 
trehalose on TFEB expression, while trehalose may indirectly control the TFEB phosphorylation 
state and nuclear translocation, via the adenosine 5'-monophosphate-activated protein kinase 
pathway [32] or the AKT pathway [30]. However, it is unclear how p-TFEB is dephosphorylated. 
So far, the only phosphatase reported to be directly able to dephosphorylate TFEB, allowing its 
activation, is PPP3CB [39,40]. Here, we showed that trehalose has no effects on Ppp3cb expression, 
while genetic or pharmacological blockage of PPP3CB strongly reduces trehalose-induced 
dephosphorylation at p-Ser142 of TFEB and TFEB nuclear translocation. Therefore, trehalose acts 
on TFEB by modulating PPP3CB enzymatic phosphatase activity, which is required to allow 
trehalose-mediated activation of TFEB. We propose a mechanism by which this might occur.  
Trehalose induces rapid, partial and transient lysosomal damage and permeabilization, with 
Ca2+ release and PPP3CB-induced TFEB nuclear translocation. Subsequent induction of autophagy, 
perhaps to heal lysosomal damage, might lead to activation of autophagy and clearance of 
aggregated neurotoxic deposits, possibly as a side effect (Figure 10).  
To support our model we found, to our surprise, that trehalose induces transient changes in 
lysosomal morphology, characterized by enlargement and formation of gaps in lysosome 
membranes in as much as half of the cell lysosomes. We demonstrate that such changes were 
associated with a LMP characterized by incorporation of LGALS3 and transient loss of 
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LysoTracker fluorescence.  Notably, we observed that all these events occur earlier than TFEB 
activation, suggesting that they might indeed be the cause of TFEB activation. Interestingly, the 
reduction of LysoTracker-positive lysosomes has already been linked to increased LMP and release 
of Ca2+ ions [38-40]. In line, in mouse models of retinitis pigmentosa, trehalose triggers LMP and 
autophagy [72]. Damaged lysosomes are specifically sequestered and become the target of a 
lysosome-specific form of autophagy, called lysophagy [67,68,73-76]. Pharmacological induction 
of LMP has been previously shown to trigger oxidative stress, and inflammation, ultimately leading 
to apoptosis or necrosis [68,75]. However, it has been reported that a transient damage on a limited 
pool of lysosomes can be reversible and may specifically induce rapid lysophagy [66]. Thus, 
lysophagy is fundamental to sequester damaged lysosomes restoring the normal pool of lysosomes 
via a TFEB-dependent lysosomal biogenesis.  
How could trehalose cause LMP? Our ultrastructural analysis indicates that, in trehalose-
treated cells, a fraction of lysosomes are bloated and present evident gaps in their limiting 
membrane. Thus, trehalose might trigger LMP by lysosomal osmotic stress which will release 
lysosomal Ca2+ activating PPP3 and consequently TFEB dephosphorylation and activation. 
Whether trehalose is imported into lysosomes to cause osmotic stress remains to be determined. 
While this mechanism removes damaged lysosomes via lysophagy, the associated upregulation of 
autophagy regulators is used to clear other damaged or aberrant components from neurons, most 
notably polyQ-containing proteins, or other ND-associated misfolded proteins. Alteration of 
lysosomal dynamics have also been described in PD. Indeed, lysosomal breakdown and 
accumulation of autophagosomes is detectable in PD brain samples in association with Lewy 
bodies. TFEB activation restores the number of lysosomes via an increased turnover of 
autophagosomes [34]. Thus, trehalose might exert a protective function in PD primarily because of 
its ability to activate TFEB restoring normal lysosomal function. 
We observed that trehalose induces, in a TFEB-dependent manner, the expression of the 
genes coding for BECN1, ATG10, ATG12, SQSTM1/p62 and MAP1LC3B, which are all required 
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for autophagy activation, as well as of PPARGC1A, which is both a target and an inducer of TFEB 
expression [77]. Trehalose also induced Zkscan3 expression, which acts as a physiological TFEB 
antagonist. This effect was independent of TFEB activation and it might be a feedback mechanism 
to restore basal autophagy levels with pathways different from those controlled by TFEB. Trehalose 
also modulated key components (HSPB8 and BAG3) of the CASA complex which delivers 
misfolded proteins to autophagosomes. Here, TFEB was marginally involved, but HSPB8, 
SQSTM1/p62, MAP1LC3B and ATG12 levels all increase 48 h after trehalose treatment, indicating 
that other pathways might coordinate the response to the drug. It is the combined activities of these 
regulators that ultimately enhance autophagic clearance of the insoluble ARpolyQ, TARDBP and 
mutant SOD1 species causative of  neurodegeneration [51]. 
 Unfortunately, in human, trehalose cannot be given orally because it is degraded by the 
TREH present in the gastrointestinal tract. Notably, the lack of TREH enzymatic activity in the gut, 
detected in the Greenland population, has no consequence on blood glucose concentration and has 
no impact on human health [69]. This suggests that trehalose could be potentially administered 
intravenously, but this would require its registration as an approved drug and it would likely 
decrease compliance of patients to a treatment that can be currently provided as a supplement of a 
natural compound. We showed that the analogs of trehalose, melibiose and lactulose, which are 
resistant to intestinal TREH, recapitulated all its effects, indicating that they are valid and potent 
mimics of trehalose and could be highly beneficial to the treatment of NDs.  
In summary, lysosomal damage underlies TFEB-mediated activation of aggregate clearance 
induced by trehalose and such a mechanism is likely crucial to trigger neuroprotection in a number 
of currently incurable human diseases.   
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Material and Methods 
Chemicals 
The following compounds were used: D-(+)-trehalose dihydrate (100 mM, T9531), melibiose (100 
mM, M5500), lactulose (100 mM, L7877), D-(+)-glucose (100 mM, 49159), cyclosporin A (10 PM, 
30024), testosterone (10 nM, 86500), Leu-Leu methyl ester hydrobromide (LLOMe; 0.3 mM, 
L7393), CHIR 98024 (3 μM, SML1094), ascorbic acid (AA; 200 μM, A5960), retinoic acid (1 μM, 
K2625), and dbcAMP (100 μM, D0627) were purchased from Sigma-Aldrich. SB431542 (10 µM, 
1614/1), SAG (0.5 μM, 4366/10), and PMA (0.5 μM, 10009634) were purchased from Tocris 
Bioscience. LDN 193189 (0.2 mΜ, S2618) was purchased from Selleckchem. BDNF (2 ng/mL, 
450-02), GDNF (5 ng/mL, 450-10), TGFB1 (1 ng/mL, 100-21) and activin A (2 ng/mL, 120-14) 
were purchased from Protein Tech. 
 
Plasmids 
TFEB-pCDNA3 plasmid was kindly provided by Prof. A. Ballabio (Telethon Institute of Genetics 
and Medicine (TIGEM), Dulbecco Telethon Institute, Federico II University, Naples) [40]. EGFP-
LGALS3 plasmid was kindly provided by Prof. M. A. Jäättelä (Danish Cancer Society Research 
Center, Copenhagen, Denmark) [66]. The AR.Q46 plasmid codes for the mutant human AR with 46 
CAG repeat has been originally provided by Prof. M. Marcelli (Baylor College of Medicine, 
Houston, TX, USA) and already described in [55]. GFP-TARDBP-25/TDP-25 codes for the 
TARDBP C-terminal 25-kDa fragment fused with the GFP protein. The plasmid was kindly 
provided by Prof. L. Petrucelli (Mayo Clinic, Jacksonville, FL, USA) [78]. GFP-SOD1A4V and 
GFP-SOD1G93A were obtained by cloning the SOD1 gene with point mutations in the pEGFP 
plasmid (Clontech, 6084-1) [62,79]. 
 
Cell cultures and transfections 
The mouse motoneuron-like hybrid cell line (NSC34) [80,81] was cultured in DMEM high-glucose 
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medium (EuroClone, ECB7501L) supplemented with 5% fetal bovine serum (Sigma-Aldrich, 
F7524), 1 mM L-glutamine (EuroClone, ECB3004D), and antibiotics (penicillin, SERVA, 
31749.04; streptomycin, SERVA, 35500.01), and grown at 37°C in 5% CO2. Cells treated with 
sugars were seeded in DMEM low glucose (EuroClone, ECM0749L) to avoid hyperosmotic shock. 
NSC34 were transfected with 0.7 Pg of DNA plasmid using Lipofectamine® (ThermoFisher 
Scientific, 18324012) and TRF/transferrin (Sigma-Aldrich, T8150). 
In all the silencing experiments, NSC34 cells were transfected with 20-40 pmole Tfeb 
siRNA (sense: 5' GGAUCAAGGAGCUGGGAAUUU 3', antisense: 5' 
AUUCCCAGCUCCUUGAUCCUU 3'), Ppp3cb siRNA (sense: 5' 
UGACAGAAAUGUUGGUAAAUU 3'; antisense: 5' UUUACCAACAUUUCUGUCAUU 3') or 
non-targeting siRNA (sense: 5' UAGCGACUAAACACAUCAAUU 3'; antisense: 5' 
UUGAUGUGUUUAGUCGCUAUU 3') using Lipofectamine® 2000 (ThermoFisher Scientific, 
11668019). All siRNAs were purchased from Dharmacon. 
 
IPSCs cultures and differentiation 
iPSCs were obtained in the lab of Dr. Kennet Fishbeck and Dr. Christopher Grunseich (NIH, 
Bethesda, MD, USA) from SBMA patient fibroblasts. iPSCs were cultured on Matrigel (Corning, 
354277) and fee with E8 (ThermoFisher Scientific, A1517001). Every 5-6 days, cells were split 
using Accutase (ThermoFisher Scientific, 00-4555-56), and in the first day, E8 was supplemented 
with ROCK-I (5 μM; Selleckchem, S1049). 
 
Generation of small molecules of neural progenitor cells and differentiation towards motor 
neurons 
iPSCs were differentiated into small molecules of neural progenitors cells (smNPCs) following the 
already published protocol [82]. In brief, embryo bodies were derived from iPSCs and were 
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maintained in a medium composed of DMEM-HAM'S F-12 (Euroclone, ECM0090L), Neurobasal 
medium (ThermoFisher Scientific, 21103049), N-2 supplement (ThermoFisher Scientific, 
17502048) and B-27™ supplement (ThermoFisher Scientific, 17504044) and antibiotics  (N2B27 
medium). Cells were treated with CHIR, SB431542, LDN 193189, SAG, and AA. After 6 days, 
embryo bodies were dissociated and plated on Matrigel (hESC-qualified Matrix; Corning®, 
354277) in a medium composed of N2B27 with CHIR, AA, and PMA. smNPCs were cultured for 
7-8 passages before starting differentiation into motoneurons. Motoneuron differentiation was 
achieved by plating smNPCs on Matrigel-coated plates at 300,000 cell/mL in N2B27 medium 
supplemented with AA, CHIR, BDNF, GDNF, and retinoic acid. After 6 days, Patterning medium 
was changed to Maturation medium (N2B27 supplemented with dbCAMP, AA, GDNF, BDNF, 
TGFB1, and Activin A (only in the first two days). After two days, the cells were split and plated at 
200,000 cell/well in a 12-well plate, and maintained in maturation medium up to 10 days. 
 
Real-time quantitative polymerase chain reaction (RT-qPCR) 
For RT-qPCR, cells were seeded at 180,000 cell/well in 6-well plates transfected/treated as 
explained in the text, and incubated for 48 h. Total RNA was extracted using Tri-Reagent (Sigma-
Aldrich, T9424) following the manufacturer’s protocol. RNA was quantified using a NanoDrop 
2000 (ThermoFisher Scientific, ND-2000) and 1 Pg per sample was treated with DNAse and 
reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit (ThermoFisher 
Scientific, 4368814). The primer sequences are listed in Table S1. 
RT-qPCR was carried out using the CFX96 Real Time System (Bio-Rad Laboratories), the 
iTaq SYBR Green Supermix (Bio-Rad Laboratories, 1725124), and with 500 nmol primers. Data 
were normalized using Rplp0. The experiments were performed with 4 independent samples (n=4). 
Western blotting and filter retardation assay 
For WB and FRA, cells were seeded at 90,000 cell/well in 12-well plates, transfected/treated as 
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explained in the text and incubated for 48 h. The cells were collected and centrifuged at 100 g for 5 
min. at 4°C. The pellets were resuspended in phosphate-buffered saline (PBS; Sigma-Aldrich, 
P4417) supplemented with Protease Inhibitor Cocktail (Sigma-Aldrich, P8340) and an ultrasonic 
homogenization was performed. The protein concentration was quantified with the bicinchoninic 
acid method using a Quantum Protein Assay Kit (Euroclone, EMP014500). 
For WB analysis, 15 Pg of total proteins was loaded, and 10% (or 15%) sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis was performed. The gels were electro-transferred to a 
nitrocellulose membrane using a Trans-turbo transfer System (Bio-Rad Laboratories, 1704150).  
For FRA, 1.5 Pg (for AR.Q46), 9 Pg (for GFP-TARDBP-25) or 6 Pg (for GFP-SOD1 
plasmids) of total proteins were filtered on a  0.2-Pm cellulose acetate membrane (Whatman GE 
Healthcare, GEH10404180) using a Bio-Dot SF Microfiltration Apparatus (Bio-Rad Laboratories, 
1703938).  
To perform nuclear-cytoplasmic TFEB localization by WB, NSC34 were seeded at 180,000 
cell/well in 6-well plates, transfected/treated as explained in the text and incubated for 48 h. The 
cells were collected and centrifuged at 375 g for 5 min. at 4°C. The pellets were lysed in Triton X-
100 lysis buffer (50 mM Tris-HCl, pH 7.5, 0.5% Triton X-100 (Sigma-Aldrich, X100), 137.5 mM 
NaCl, 10% glycerol (Sigma-Aldrich, G5516), 5 mM ethylenediaminetetraacetic acid) containing 
protease inhibitor cocktail (Sigma-Aldrich, P8340) and the nuclear-cytoplasmic fractions were 
isolated as described previously [77].  
The membranes obtained by WB or FRA were immunoblotted using the following 
antibodies: anti-SQSTM1/p62 (Abcam, ab91526; 1:2,000); anti-LC3A/B (Sigma-Aldrich, L8918, 
1:2,000); anti-TFEB (Bethyl Laboratories, A303-673A, 1:4,000), anti-phospho-TFEB (Ser142; 
Merck-Millipore, ABE1971; 1:3,000), anti-GAPDH (FL-335; Santa-Cruz Biotechnology,  sc-
25778; 1:3,000), anti-AR (H280; Santa Cruz Biotechnology, sc-13062; 1:1,000), anti-histone H3 
 24 
(Abcam, ab1791; 1:40,000), anti-GFP (Abcam, AB1218; 1:2,000). The primary antibodies were 
prepared in 5% non-fat dried milk (Euroclone, EMR180500) in TBS-T (Tris base 20 mM, NaCl 140 
mM, pH 7.6 and 0.01% Tween 20 (Sigma-Aldrich, P1379)). 
Immunoreactivity was detected using secondary peroxidase conjugated goat anti-rabbit IgG-
HRP (Jackson Immunoresearch Laboratories, 111-035-003: 1:5,000) and enhanced 
chemiluminescent (ECL) detection reagent (Clarity™ ECL western Blotting substrate; Bio-Rad 
Laboratories, 1705060). Images were acquired using a Chemidoc XRS System (Bio-Rad 
Laboratories, 1708265) and densitometric quantification was performed using Image Lab Software, 
version 5.2.1 (Bio-Rad Laboratories). 
Immunofluorescence analysis (IF)  
For IF analysis, the cells were seeded at 35,000 cells/well in 24-well plates on 13-mm coverslips, 
transfected/treated as explained in the text and incubated for 48 h. The cells were fixed with 4% 
paraformaldehyde in PBS and then permeabilized in 0.2% Triton X-100 in PBS for 10 min. The 
cells were incubated with primary antibody anti-TFEB (Bethyl Laboratories, 1:400) in 5% non-fat 
dried milk- TBS-T blocking solution, and then with secondary antibody goat anti-rabbit Alexa 
Fluor® 488 (ThermoFisher Scientific, A11070; 1:1,000) in  5% non-fat dried milk (EuroClone, 
EMR0145000) TBS-T blocking solution. Nuclei were stained with DAPI (1:10,000 in PBS). 
Coverslips were mounted onto slides with Mowiol® 4-88 (Merck-Millipore, 475904) and analyzed 
with an LSM510 Meta system confocal microscope (Zeiss) and images were processed with the 
Aim 4.2 software (Zeiss). 
 
Image analysis 
TFEB nuclear intensity was measured using ImageJ software. For each treatment, 100 cells were 
analyzed and a value of intensity per nucleus was measured. 
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Measurement of lysosomal membrane permeabilization by lysosomal LGALS/galectin puncta 
assay 
To perform a lysosomal LGALS/galectin puncta assay, NSC34 were plated at 35,000 cell/well in 
24-well plates on 13-mm coverslips and transfected with 0.4 Pg of GFP-LGALS3/Galectin3 
plasmid. The cells were treated with 100 mM trehalose, melibiose, lactulose or glucose (as negative 
control) for different time periods. LLOMe was included as a positive control for LMP (0.3 mM for 
1 h). The cells were fixed as described above, and quantification of cells with > 3 EGFP-LGALS3 
puncta was performed by manual counting of 3 fields per sample, using a PL 10X/20 eyepiece with 
graticules (100 mm x 10 mm in 100-grid divisions) as described in [66]. The fields were randomly 
selected and at least 100 cells for sample were counted (n=3).  
Measurement of lysosomal membrane permeabilization by cytometer analysis 
NSC34 cells were seeded at 90,000 cell/well in 12-well plates and treated with 100 mM trehalose 
for different time periods (from 2 to 48 h). The cells were incubated with 100 nM of the 
lysosomotropic probe LysoTracker Green DND-26 (ThermoFisher Scientific, L7526) for 30 min. 
The cells were collected, resuspended in 4% FBS in PBS and analyzed on a NovoCyte flow 
cytometer (Acea Biosciences, Inc.).  Mean LysoTracker fluorescence intensity was recorded from 
50,000 cells for each sample (n=4). 
 
Stimulated emission depletion microscopy (STED)  
NSC34 cells were plated at 35,000 cell/well in 24-well plates on 13-mm coverslips and transfected 
with 0.4 μg of GFP-LGALS3/Galectin3 plasmid. The cells were treated with 100 mM trehalose for  
6 h. The cells were fixed for 25 min with 4% paraformaldehyde in PBS at 37°C and then 
permeabilized in 0.2% Triton X-100 in PBS for 10 min. The cells were incubated with primary 
antibody anti-LAMP1 (Abcam, AB24170; 1:1,000) in 5% non-fat dried milk-TBS-T blocking 
solution, and then with secondary antibody anti-rabbit IgG-Atto647N (Sigma-Aldrich, 40839; 
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1:400) in 5% non-fat dried milk-TBS-T blocking solution. Coverslips were mounted onto slides 
with Mowiol® 4-88 (Merck-Millipore, 475904) and analyzed with a Leica TCS SP8 STED 3X with 
3 depletion lines (592 nm, 660 nm and 775 nm), with HC PL APO 100X/1.40 oil objective. Images 
were acquired through the Software Leica LAS X and processed using ImageJ (version 1.51). 
 
Electron microscopy analysis 
NSC34 cells were seeded at 180,000 cell/well in a 2-well Nunc® Lab-Tek®Chamber Slide™ 
system (Nunc, C6682). The cells were treated with 100 mM trehalose for different times, and then 
fixed using 2.5% glutaraldehyde (Sigma-Aldrich, G7776) in 0.1 M sodium cacodylate buffer 
(Sigma-Aldrich, C0250), pH 7.4 for 1 h at room temperature. The cells were postfixed in osmium 
tetroxide (Electron Miscroscopy Science, 19100) for 2 h, and 1% uranyl acetate (SERVA 
Electrophoresis, 77870) for 1 h. Subsequently, samples were dehydrated through a graded ethanol 
series and flat embedded in resin EMBED-812 (Electron Microscopy Science, 14120) for 24 h at 
60°C. Ultrathin sections (50 nm) were cut parallel to the substrate, stained with 5% uranyl acetate in 
50% ethanol and observed with a CM10 electron microscope (Philips, Eindhoven, The 
Netherlands). Digital images were taken with a Megaview 3 camera. Analysis of morphologically 
identified double-membrane autophagic vacuoles (AV) and single-membrane lysosomes (Lys) 
number and diameters was assessed in 10 cells for each treatment. The diameter of these structures 
was measured with an iTEM software package (Olympus-SYS; Olympus Corporation) and plotted 
as box plots [83]. 
 
 
Statistical analysis 
The data are presented as mean ± SD. Statistical analysis has been performed by using Student’s t-
test to compare 2 groups. To compare 3 or more groups were made analysis of variance (ANOVA): 
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One-Way ANOVA to compare the effect of one variable or Two-Way ANOVA to compare the 
effect of 2 independent variables. P value < 0.05 was considered statistically significant. When 
ANOVA was significant, we performed a post hoc test (see figure legends for details). Analyses 
were done with the PRISM (version 5) software (GraphPad Software). Statistical analysis for the 
EM experiments was performed using the Mann-Whitney test and Kruskal-Wallis test, means were 
considered significantly different if P<0.05. 
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Legend to figures 
 
Figure 1. Trehalose activates TFEB nuclear translocation and induces protein quality control genes. 
(A-M) NSC34 cells were treated with 100 mM trehalose or glucose (as control) for different times. 
(A) IF analysis performed with anti-TFEB antibody (green), nuclei were stained with DAPI (blue) 
(63X magnification). Scale bar: 10 Pm. (B) The bar graph represents the quantification of TFEB 
nuclear intensity; the fields were randomly selected and at least 100 cells for each sample were 
analyzed (n=3) (*p< 0.05, ** p< 0.005, *** p< 0.001, one-way ANOVA with Tukey’s test). (C) 
WB analysis of cytoplasmic (C) and nuclear extracts (N).  GAPDH and histone H3 were used as 
loading controls for cytoplasmic and nuclear fractions, respectively.  (D-M) RT-qPCR analyses. 
The relative fold difference in mRNA expression was determined using t=0 as internal control. Data 
are means ± SD of 4 independent samples. RT-qPCR on the following mRNA: Tfeb (D); Zkscan3 
(E); Sqstm1/p62 (F); Map1lc3b (G); Atg10 (H); Atg12 (I); HspB8 (J); Bag3 (K); Becn1 (L); 
Ppargc1A (M). Bar graphs represent the relative fold induction of these genes (*p< 0.05, ** p< 
0.005, *** p< 0.001, one-way ANOVA with Tukey’s test).   
 
Figure 2. TFEB silencing counteracts trehalose-induced expression of autophagic genes. (A-N) 
NSC34 cells were transfected with Tfeb or non-targeting (as control) siRNAs and treated with 100 
mM glucose or trehalose. (A) WB analysis was performed, and the bar graphs (B-C) represent the 
mean relative optical density of SQSTM1/p62 and MAP1LC3B-II:MAP1LC3B-I protein 
expression levels, respectively, performed with n = 3 independent samples. LC3-II:LC3-I ratio was 
calculated by densitometric analysis of both bands. (*** p< 0.001, two-way ANOVA with Tukey’s 
test.) (D-N) RT-qPCR for the following mRNA: Tfeb (D); Zkscan3 (E); Ppargc1a (F); Sqstm1/p62 
(G); Lc3 (H); HspB8 (I); Ctsb (J); Gla (K); Lamp2A (L); Mcoln1 (M); Tpp1 (N); the bar graphs 
represent the relative fold induction of these genes normalized with Rplp0 mRNA levels. Data are 
means ± SD of 4 independent samples (** p< 0.005, *** p< 0.001, two-way ANOVA with 
Bonferroni’s test).  
 
Figure 3. TFEB silencing counteracts trehalose-induced pro-degradative effects. (A-C) NSC34 
cells were transfected with Tfeb siRNA or non-targeting siRNAs, and with AR.Q46, untreated or 
treated with 100 mM trehalose, in absence or in presence of 10 nM testosterone for 48 h. (A) WB 
analysis and (B) FRA were performed. (C) The bar graph represents the mean relative optical 
density of FRA ± SD for n = 3 independent samples (*** p< 0.001, two-way ANOVA with 
Bonferroni’s test). (D) WB analysis on iPSCs derived from SBMA patient (Q51) and differentiated 
to motoneuronal-like cells for 10 days in absence or in presence of 10 nM testosterone, and treated 
with 100 mM trehalose for the last 48 h. WB blot analysis was performed. Histone H3 was used for 
loading control. (E-G) NSC34 cells were transfected with Tfeb siRNA or non-targeting siRNA, and 
with GFP-TARDBP-25 for 48 h, untreated or treated with 100 mM trehalose for 48 h (E) WB 
analysis and (F) FRA were performed. (G)The bar graph represents the mean relative optical 
density of FRA ± SD for n = 3 independent samples (*p< 0.05, two-way ANOVA with 
Bonferroni’s test). (H-M) NSC34 cells were transfected with Tfeb siRNA or non-targeting siRNA, 
and with mutant GFP-SOD1 (SOD1A4V and G93A), for 48 h, untreated or treated with 100 mM 
trehalose for 48 h.  WB analysis (H, K) and FRA were performed (I,L). (J,M) The bar graphs 
represent the mean relative optical density of FRA ± SD for n = 3 independent samples (*p< 0.05, 
two-way ANOVA with Bonferroni’s test). For WB experiments, GAPDH was used as an internal 
loading control.  
 
Figure 4. Trehalose-induced TFEB activation is mediated by PPP3CB activity. (A-C) NSC34 were 
transfected with Ppp3cB or non-targeting siRNA, and treated with 100 mM trehalose or untreated 
(as control) for 48 h. (A) WB analysis of cytoplasmic (C) and nuclear extracts (N). (B) IF analysis 
performed with anti-TFEB antibody (green), nuclei were stained with DAPI (blue) (63X 
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magnification). Scale bar: 10 Pm. (C) The bar graph represents the quantification of TFEB nuclear 
intensity; the fields were randomly selected and at least 100 cells for each sample were analyzed 
(n=3) (*p< 0.05, ** p< 0.005, *** p< 0.001, one-way ANOVA with Tukey’s test). (D) RT-qPCR 
for Ppp3cB mRNA performed on NSC34 cells treated with 100 mM trehalose or untreated (as 
control) for 48 h. The relative fold difference of mRNA expression was determined using untreated 
samples as internal control. Data are means ± SD of 4 independent samples. (E) WB analysis of 
cytoplasmic (C) and nuclear extracts (N) on NSC34 cells treated (or untreated) with 100 mM 
trehalose, in the absence or in presence of 10 µM CsA) for 1 h. (F) The bar graph represents mean ± 
SD for n = 4 independent samples of nuclear:cytoplasmic TFEB ratio compared to control (*p< 
0.05, ** p< 0.005, one-way ANOVA with Tukey’s test). (G-H) For the determination of TFEB 
phosphorylation levels at Ser142, NSC34 were transfected with TFEB and treated with 100 mM 
glucose or 100 mM trehalose in the absence or in presence of 10 PM CsA for 1 h. (G) WB analysis 
and (H) WB analysis of cytoplasmic (C) and nuclear extracts (N) were performed. For WB 
fractionation experiments, GAPDH and histone H3 were used as an internal loading control for 
cytoplasmic and nuclear fraction, respectively.   
Figure 5. Electron microscopy analysis of trehalose effects on lysosome morphology. (A) NSC34 
cells were treated with 100 mM trehalose for the indicated times and processed for electron 
microscopy. Lys, lysosome. Scale bar: 500 nm. (B) Quantification of the diameter of autophagic 
vesicles (AV) and lysosomes (Lys) in control (CTR) and trehalose-treated cells at different times. 
Examples of the morphology of the quantified organelles are shown below the graph. Scale bar: 200 
nm. (C) High-scale magnification of an enlarged and damaged lysosome. Arrows point to gaps in 
the limiting membrane. Please note that the electron-dense material in the lysosomal lumen is 
sparse, a feature that is never observed in untreated cells. (D) Quantification of the number of 
lysosomes presenting gaps on their limiting membrane in control cells and cells treated as indicated 
(*p< 0.05, *** p< 0.001 non-parametric one-way ANOVA with Kruskal-Wallis test). (E) WB 
analysis was performed on NSC34 cells treated with 100 mM trehalose or glucose (as control) for 
different time periods.  
Figure 6. Trehalose induces lysosome membrane permeability. NSC34 cells were transfected with 
a plasmid encoding EGFP-LGALS3, and treated with 100 mM trehalose for different time periods 
or with 0.3 mM LLOMe for 1 h as a positive control. (A) Fluorescence microscopy analysis on cells 
treated with trehalose for 2 or 6 h, or with LLOMe (63X magnification). Scale bar: 10 Pm. (B)The 
bar graph shows the quantification of percentage of cells with > 3 EGFP-LGALS3 puncta after 
trehalose treatment at different time points; the fields were randomly selected and at least 100 cells 
for each sample were counted (n=3). (** p< 0.005, *** p< 0.001, one-way ANOVA with Tukey’s 
test.) (C) WB analysis of EGFP-LGALS3 protein levels, GAPDH was used as a loading control (D) 
Cells treated as in A and labeled with anti-LAMP1 (red) to visualize lysosomes were analyzed by 
STED microscopy. Arrows point to examples of EGFP-LGALS3 (green)-positive lysosomes. Scale 
bar: 10 Pm (E) Cytofluorimetric analysis performed on NSC34 cells treated with trehalose for 
different time periods, and labelled with LysoTracker Green. Mean fluorescence intensity was 
measured (n=4) (*** p< 0.001, one-way ANOVA with Tukey’s test).  
 
Figure 7. Melibiose and lactulose induce TFEB nuclear translocation. (A) IF analysis of TFEB 
localization performed on NSC34 cells treated with 100 mM trehalose, 100 mM melibiose or 100 
mM lactulose for 48 h. Nuclei were stained with DAPI (blue) (63X magnification). Scale bar: 10 
Pm. (B) WB analysis of cytoplasmic (C) and nuclear extracts (N) on NSC34 cells untreated 
(control) or treated with 100 mM melibiose or 100 mM lactulose for 48 h. GAPDH and histone H3 
were used as internal loading control for cytoplasmic and nuclear fractions, respectively. (C) The 
bar graph represents the mean ± SD for n = 4 independent samples of nuclear:cytoplasmic TFEB 
ratio compared to untreated cells (*p< 0.05 one-way ANOVA with Tukey’s test).   
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Figure 8. Melibiose and lactulose effects are mediated by PPP3CB: induction of ALP gene 
expression and LMP. (A-B) WB analysis of cytoplasmic (C) and nuclear extracts (N) of NSC34 
cells untreated (control) or treated with 100 mM melibiose (A) or 100 mM lactulose (B) in the 
absence or presence of 10 PM CsA for 1 h. GAPDH and histone H3 were used as internal loading 
controls for cytoplasmic and nuclear fractions, respectively. (C-H) RT-qPCR on NSC34 cells 
untreated (control) or treated with 100 mM trehalose, 100 mM melibiose or 100 mM lactulose for 
48 h. The relative fold difference of mRNA expression was determined using untreated samples as 
internal control. Data are means ± SD of 4 independent samples. RT-qPCR for the following 
mRNA: Tfeb (C); Zkscan3 (D); Sqstm1/p62 (E); Map1Lc3b (F); Hspb8 (G); Bag3 (H). Bar graphs 
represent the relative fold induction of these genes (*p< 0.05, ** p< 0.005, *** p< 0.001, one-way 
ANOVA with Tukey’s test). (I) Fluorescence microscopy analysis (63X magnification) performed 
on NSC34 cells that were transfected with a plasmid encoding EGFP-LGALS3, and treated with 
100 mM trehalose, 100 mM melibiose or 100 mM lactulose for 2 h; scale bar: 10 Pm. (J) Bar graph 
shows the quantification of percentage of cells with > 3 EGFP-LGALS3 puncta; the fields were 
randomly selected and at least 100 cells for each sample were counted (n=3) (** p< 0.005, *** p< 
0.001, one-way ANOVA with Tukey’s test).  
 
Figure 9. TFEB mediated pro-degradative effects of melibiose and lactulose on ARpolyQ 
clearance. (A) FRA analysis performe on NSC34 cells transfected with AR.Q46, untreated or 
treated with 100 mM trehalose, melibiose or lactulose in the absence or in presence of 10 nM 
testosterone for 48 h. (B) The bar graph represents the mean relative optical density of FRA ± SD 
for n = 3 independent samples (*** p< 0.001, two-way ANOVA with Bonferroni’s test). (C-D) WB 
analysis performed on NSC34 cells transfected with Tfeb siRNA or non-targeting siRNA, and with 
AR.Q46, in absence or in presence of 10 nM testosterone for 48 h treated with 100 mM melibiose 
or lactulose, respectively.  
 
 
Figure 10. Proposed model of the mechanism of action trehalose, and its analogues: trehalose, 
melibiose and lactulose act on lysosomes inducing a transient lysosomal membrane permeability. 
This causes Ca2+ leaks which activates the phosphatase PPP3/calcineurin. PPP3 specifically de-
phosphorylates TFEB inducing its activation and nuclear translocation to activate autophagy and 
lysophagy with removal of damaged lysosomes and in parallel (if present) misfolded protein 
aggregates. 
 
 
 










